{"id":"alverine","rwe":[],"tags":[{"label":"alverine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03AX08","category":"atc"},{"label":"Active","category":"status"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:31:22.960228","allNames":"dipropylin","offLabel":[],"synonyms":["alverine hydrochloride","alverine","dipropylin","dipropyline","phenopropamine","phenpropamine","alverine citrate","alverine citrate salt"],"timeline":[],"brandName":"Dipropylin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"alverine","explanation":"Imagine your digestive tract as a long tube with muscles that help move food through it. When these muscles get too active, it can cause painful spasms and cramping. Alverine helps calm these muscles, making it easier to digest food and reducing discomfort.","oneSentence":"Alverine works by relaxing the muscles in the digestive tract to reduce spasms and cramping.","technicalDetail":"Alverine exerts its effects by interacting with smooth muscle cells in the gastrointestinal tract, leading to a decrease in muscle tone and a reduction in spasmodic activity."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Alverine","title":"Alverine","extract":"Alverine is a drug used for functional gastrointestinal disorders. Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/142","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALVERINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALVERINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Alverine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:39:28.499809","biosimilars":[],"competitors":[{"drugName":"isometheptene","drugSlug":"isometheptene","fdaApproval":"","relationship":"same-class"}],"genericName":"alverine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(57)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"isometheptene","brandName":"isometheptene","genericName":"isometheptene","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05815602","phase":"PHASE3","title":"Ebastine Versus Mebeverine in IBS Patients","status":"RECRUITING","sponsor":"Guy Boeckxstaens","startDate":"2023-03-30","conditions":["IBS - Irritable Bowel Syndrome","IBS"],"enrollment":200,"completionDate":"2028-01-01"},{"nctId":"NCT05175131","phase":"PHASE3","title":"Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders","status":"COMPLETED","sponsor":"Abbott","startDate":"2020-11-27","conditions":["Functional Bowel Disorder"],"enrollment":465,"completionDate":"2021-05-18"},{"nctId":"NCT06914921","phase":"NA","title":"Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome.","status":"COMPLETED","sponsor":"S.LAB (SOLOWAYS)","startDate":"2024-02-04","conditions":["Irritable Bowel Syndrome (IBS)"],"enrollment":224,"completionDate":"2025-02-01"},{"nctId":"NCT05508633","phase":"PHASE2","title":"The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai Changzheng Hospital","startDate":"2022-10-28","conditions":["Portal Hypertension"],"enrollment":20,"completionDate":"2025-12"},{"nctId":"NCT06696248","phase":"PHASE2,PHASE3","title":"Carvedilol and Alverine in Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-11-15","conditions":["Hypertension, Portal"],"enrollment":30,"completionDate":"2025-09-30"},{"nctId":"NCT06473493","phase":"PHASE2,PHASE3","title":"The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06","conditions":["Hypertension, Portal"],"enrollment":30,"completionDate":"2025-03"},{"nctId":"NCT06470386","phase":"PHASE2,PHASE3","title":"The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06","conditions":["Hypertension, Portal"],"enrollment":178,"completionDate":"2025-11"},{"nctId":"NCT05867550","phase":"PHASE4","title":"To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea","status":"COMPLETED","sponsor":"Bahria University","startDate":"2023-01-03","conditions":["Irritable Bowel Syndrome With Diarrhea"],"enrollment":162,"completionDate":"2023-06-10"},{"nctId":"NCT05523427","phase":"NA","title":"Probiotics as Adjuvant Therapy in the Management of Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"University of Mosul","startDate":"2022-07-19","conditions":["Irritable Bowel Syndrome","Irritable Bowel Syndrome With Diarrhea"],"enrollment":100,"completionDate":"2023-01-06"},{"nctId":"NCT05100719","phase":"NA","title":"The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)","status":"NOT_YET_RECRUITING","sponsor":"University of Pecs","startDate":"2022-09","conditions":["Irritable Bowel Syndrome","Lactose Intolerance","Lactose Malabsorption"],"enrollment":200,"completionDate":"2026-12"},{"nctId":"NCT00934973","phase":"PHASE4","title":"Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)","status":"COMPLETED","sponsor":"Hazel Everitt","startDate":"2010-04","conditions":["Irritable Bowel Syndrome"],"enrollment":135,"completionDate":"2011-10"},{"nctId":"NCT04635566","phase":"NA","title":"Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2019-03-01","conditions":["Incontinence","Urinary Incontinence","Urinary Bladder Cancer"],"enrollment":120,"completionDate":"2020-03-01"},{"nctId":"NCT03147599","phase":"PHASE4","title":"Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2017-05-15","conditions":["Oncology","Incontinence","Incontinence, Daytime Urinary","Incontinence, Nighttime Urinary","Bladder Cancer","Orthotopic Neobladder"],"enrollment":110,"completionDate":"2019-05-01"},{"nctId":"NCT04145856","phase":"PHASE4","title":"Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico","status":"COMPLETED","sponsor":"Hospital Juarez de Mexico","startDate":"2018-09-03","conditions":["Irritable Bowel Syndrome"],"enrollment":55,"completionDate":"2019-08-27"},{"nctId":"NCT04217733","phase":"PHASE3","title":"Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome","status":"RECRUITING","sponsor":"Tanta University","startDate":"2019-11-01","conditions":["IBS - Irritable Bowel Syndrome"],"enrollment":60,"completionDate":"2030-12-30"},{"nctId":"NCT02260154","phase":"","title":"Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm","status":"COMPLETED","sponsor":"Abbott","startDate":"2015-07","conditions":["Post-cholecystectomy Gastrointestinal Spasms"],"enrollment":220,"completionDate":"2016-10"},{"nctId":"NCT03549143","phase":"","title":"Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation","status":"COMPLETED","sponsor":"Abbott","startDate":"2017-12-25","conditions":["Irritable Bowel Syndrome"],"enrollment":1000,"completionDate":"2019-04-19"},{"nctId":"NCT01404923","phase":"PHASE4","title":"Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)","status":"COMPLETED","sponsor":"Laboratoires Mayoly Spindler","startDate":"2009-12","conditions":["Irritable Bowel Syndrome"],"enrollment":436,"completionDate":"2011-10"},{"nctId":"NCT01678781","phase":"","title":"Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide","status":"COMPLETED","sponsor":"Abbott","startDate":"2012-07","conditions":["Irritable Bowel Syndrome"],"enrollment":607,"completionDate":"2013-08"},{"nctId":"NCT00542295","phase":"PHASE4","title":"Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Laboratoires Mayoly Spindler","startDate":"2007-07","conditions":["Irritable Bowel Syndrome"],"enrollment":400,"completionDate":"2008-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"001763","UNII":"46TIR1560O","CHEBI":"CHEBI:518413","INN_ID":"95","RXNORM":"17627","UMLSCUI":"C0051528","ChEMBL_ID":"CHEMBL253371","KEGG_DRUG":"D02877","DRUGBANK_ID":"DB01616","PUBCHEM_CID":"3678","SNOMEDCT_US":"349818006","SECONDARY_CAS_RN":"5982-87-6","MESH_SUPPLEMENTAL_RECORD_UI":"C010846"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":57,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"A03AX08","allCodes":["A03AX08","A03AX58"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 25","pmid":"41866875","title":"Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome.","journal":"The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology"},{"date":"2026 Apr 1","pmid":"41644045","title":"Screening strategy using a filamentous fungus model to repurpose drugs for mitochondrial complex I deficiencies.","journal":"Life sciences"},{"date":"2026 Jan 15","pmid":"41598660","title":"Revisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.","journal":"Journal of clinical medicine"},{"date":"2025","pmid":"39850659","title":"Structure-based identification of HNF4α agonists: Rosmarinic acid as a promising candidate for NAFLD treatment.","journal":"Computational and structural biotechnology journal"},{"date":"2024 Oct","pmid":"38906512","title":"Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension.","journal":"Gastroenterology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dipropylin, also known as Alverine, is a small molecule drug in the alverine class. Its exact target is unknown, but it is used to treat gastrointestinal spasms and irritable bowel syndrome. The commercial status of Alverine is unclear, but it is likely available as a generic medication. Key safety considerations include potential gastrointestinal side effects. Alverine's mechanism of action is not well understood, but it is thought to work by relaxing smooth muscle in the gastrointestinal tract.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}